Clinical trials: Transmission
HIV Infections
Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)
Implementation of a model for access and retention of HIV care for vulnerable and excluded population using a mobile screening unit and a strategy of diagnosis and initiation of treatment with Bictegravir (BIC) 50 mg/…
- Trial name
- SIMPLIFIED (NCT05405751)
- Testing
- Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- Where
- Spain
- Volunteers
- 101 people
- Sponsor
- Fundacion SEIMC-GESIDA
AIDS
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
- Trial name
- NCT00972725
- Testing
- GSK Biologicals' HIV vaccine (732461), Chloroquine
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3…
- Trial name
- NCT00571961
- Testing
- Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV Infections
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
This is an active control, randomized study to investigate the safety, tolerability and PK of repeat dose administration of long-acting CAB 400 mg/mL formulation intramuscular (IM) (gluteus medius and vastus lateralis) and…
- Trial name
- NCT04484337
- Testing
- Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
Antiretroviral therapy (ART) can reduce HIV to very low levels in the blood, but it cannot cure HIV infection because a small amount of virus remains in cells as a hidden (latent) form.
- Trial name
- NCT01933594
- Testing
- Romidepsin
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Sexually Transmitted Diseases
Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women
The proposed intervention is a web-based intervention guided by theoretical components to increase HIV home testing among Black women at risk for HIV and sexually transmitted infections (STIs) in a HIV hotspot in the South.
- Conditions
- Hiv, Sexually Transmitted Diseases, Economic Problems
- Trial name
- NCT05390541
- Testing
- Empowered to Test Yourself, Educational Control
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer.
- Trial name
- NCT00604175
- Testing
- Quadrivalent HPV vaccine
- Where
- 61 sites in United States, Brazil and 2 more
- Volunteers
- 319 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
This study will evaluate the safety and virologic effect of an experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), alone or in combination with antiretroviral therapy (ART), in adults during early acute HIV…
- Trial name
- NCT02591420
- Testing
- VRC01, Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
- Where
- 5 sites in Kenya, Tanzania and 2 more
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir…
- Trial name
- NCT01565850
- Testing
- D/C/F/TAF, DRV, COBI
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
Risk Behavior, HIV/AIDS
Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs
This study will evaluate the efficacy and cost-effectiveness of CHRP-BB - an integrated bio-behavioral approach that incorporates the use of PrEP - with an evidence-based behavioral approach aimed at enhancing PrEP adherence and…
- Conditions
- Risk Behavior, HIV/AIDS, Medication Adherence, Substance Abuse
- Trial name
- CHRP-BB (NCT03282890)
- Testing
- CHRP-BB
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- University of Connecticut
Infection, Human Immunodeficiency Virus
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
GSK has in-licensed a novel NNRTI-class candidate (GSK2248761, IDX12899) for the treatment of subjects with HIV-1 infection from Idenix Pharmaceuticals.
- Trial name
- NCT00945282
- Testing
- GSK2248761, Lopinavir/ritonavir, HAART
- Where
- Argentina
- Volunteers
- 8 people
- Sponsor
- ViiV Healthcare
Tobacco Use Cessation
Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study
The goal of this research study is to learn about 2 different interactive methods that are designed to help people with HIV/AIDS stop smoking.
- Trial name
- NCT02302859
- Testing
- Nicotine Patch, Questionnaires, Pamphlet
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Cardiovascular Disease, HIV Infection
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL)…
- Trial name
- HALO (NCT00795717)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Tufts University
Human Papillomavirus (HPV) Infection
GARDASIL Reexamination Study (V501-059)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting…
- Trial name
- NCT01062074
- Volunteers
- 3,605 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Human Immunodeficiency Virus I
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested at Week 96.
- Trial name
- SPRING-2 (NCT01227824)
- Testing
- GSK1349572 (dolutegravir), raltegravir, ABC/3TC
- Where
- 101 sites in United States, Australia and 7 more
- Volunteers
- 828 people
- Sponsor
- ViiV Healthcare
Gonococcal Infection
Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae
This study is a multi-center, single-arm, open-label clinical study to assess the efficacy of one dose of ciprofloxacin given orally in subjects infected with untreated gyrase A (gyrA) serine 91 genotype Neisseria gonorrhoeae (N.
- Trial name
- NCT02961751
- Testing
- Ciprofloxacin
- Where
- 9 sites in United States
- Volunteers
- 211 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy Related
Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ
"SKILLZ," is a mixed methods evaluation of the Grassroots Soccer (GRS) SKILLZ Package based in Lusaka, Zambia. The package is made up of three football-based programs: (1) SKILLZ-Girl - implemented in schools as part of a 10-week…
- Conditions
- HIV Infections, Pregnancy Related, STI, Mental Health Wellness 1
- Trial name
- SKILLZ (NCT04429061)
- Testing
- SKILLZ-Girl curriculum
- Where
- Zambia
- Volunteers
- 2,153 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV Infections
Combination Vaccination Before HIV Treatment Interruption
The purpose of this study is to determine if vaccination before a structured treatment interruption (STI) is associated with an improvement in immune function, resulting in a delayed and reduced rebound in the amount of HIV virus…
- Trial name
- NCT00212888
- Testing
- Remune and ALVAC
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Coronary Artery Disease, Human Immunodeficiency Virus
Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
The investigators are studying whether an anti-inflammatory intervention improves impaired coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease (CAD).
- Trial name
- NCT02624180
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.